Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US

Introduction: This study evaluated the cost-effectiveness of atezolizumab + chemotherapy vs. chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (SCLC) in the United States (US). Methods: The three health states partitioned survival (PS) model was used over the lifetime....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yingcheng, Rui, Mingjun, Yang, Lan, Wang, Xintian, Shang, Ye, Ma, Aixia, Li, Hongchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055835/
https://www.ncbi.nlm.nih.gov/pubmed/33889559
http://dx.doi.org/10.3389/fpubh.2021.650392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055835/
https://www.ncbi.nlm.nih.gov/pubmed/33889559
http://dx.doi.org/10.3389/fpubh.2021.650392

Ejemplares similares